A Study of LUCAR-G79 in Subjects With Relapsed/Refractory Autoimmune Diseases

PHASE1RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 17, 2025

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2030

Conditions
Relapsed/Refractory Autoimmune Diseases
Interventions
BIOLOGICAL

LUCAR-G79 T cells

Prior to infusion of the LUCAR-G79 T cells, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.

Trial Locations (6)

Unknown

RECRUITING

The Third The People's Hospital of Bengbu, Bengbu

NOT_YET_RECRUITING

Affiliated Hospital of Nantong University, Nantong

NOT_YET_RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

RECRUITING

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

NOT_YET_RECRUITING

Shanghai Zhongshan Hospital, Shanghai

NOT_YET_RECRUITING

The second Affiliated Hospital of Xi'an Jiaotong University, Xi’an

Sponsors
All Listed Sponsors
lead

Nanjing Legend Biotech Co.

INDUSTRY